Rachel Beairsto reporting for the Cardiology Advisor writes that a new study shows diabetes duration increases risk of cardiorenal effects developing. However, both glucagon-like-peptide-1 analogs liraglutide and semaglutide appear to reduce risk for cardiorenal outcomes effectively regardless of diabetes duration. The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) and SUSTAIN-6 trials (Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) demonstrated that glucagon-like peptide-1 receptor agonists liraglutide and semaglutide reduce cardiovascular risk in patients with type 2 diabetes (T2D).
To investigate the effects of T2D duration on the cardiorenal efficacy of liraglutide and semaglutide, researchers conducted a post-hoc analysis of LEADER and SUSTAIN-6 in which 9340 participants with T2D and high cardiovascular risk were randomly assigned to receive liraglutide or semaglutide and 3297 were assigned to a placebo group,
The results indicated that patients with a longer duration of T2D were older, more often women, and had worse renal function and higher rates of peripheral artery disease and insulin use. The study was funded by Novo Nordisk.